-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mirabegron ER in Esophageal Achalasia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirabegron ER in Esophageal Achalasia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirabegron ER in Esophageal Achalasia Drug Details: Mirabegron (Betanis, Myrbetriq, Myrbetric,...
-
Product Insights
Net Present Value Model: Beova
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Beova Drug Details Vibegron (Beova, Gemtesa)...
-
Product Insights
Net Present Value Model: Betanis/Myrbetriq/Betmiga
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Betanis/Myrbetriq/Betmiga Drug Details Mirabegron (Betanis, Myrbetriq,...
-
Product Insights
Net Present Value Model: Gemtesa
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Gemtesa Drug Details Vibegron (Beova, Gemtesa)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – mirabegron ER
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry mirabegron ER Drug Details Mirabegron (Betanis, Myrbetriq, Myrbetric, YM178) is a smooth muscle relaxant,...
-
Sector Analysis
Overactive Bladder: Global Drug Forecast and Market Analysis to 2030
The overactive bladder (OAB) market sales have been valued at $2.2 billion in 2020 across the eight major markets (8MM) covered in this report- the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan and China. The market is projected to grow at a CAGR of more than 2% during the period 2021-2030. The US accounted for the largest market with global sales in 2020, equating to a market share of more than 45%. This largely reflects the large...
-
Sector Analysis
Overactive Bladder – Epidemiology Forecast to 2030
Overactive bladder (OAB) syndrome is a group of urinary symptoms, defined as urinary urgency, usually with urinary frequency and nocturia, with or without urgency urinary incontinence (Abrams et al., 2003; Haylen et al., 2010). It is characterized by a frequent and sudden compelling urge to urinate that may be difficult to control. The clinical diagnosis is characterized by urinary urgency, with or without urge incontinence, usually with daytime and nighttime frequency, in the absence of a urinary tract infection or...
-
Sector Analysis
United States Cardiovascular Devices Market Outlook to 2025 – Aortic and Vascular Graft Devices, Atherectomy Devices, Cardiac Assist Devices and Others
GlobalData’s “United States Cardiovascular Devices Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States Cardiovascular Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Aortic and Vascular Graft Devices, Atherectomy Devices, Cardiac Assist Devices, Cardiac Rhythm Management Devices, Cardiovascular Prosthetic Devices, Cardiovascular Surgery Devices, Clot Management Devices, Electrophysiology Devices, Interventional Cardiology, Peripheral Vascular Devices and Prosthetic Heart Valves. The United States Cardiovascular Devices...